The ApoA-I mimetic peptide 5A enhances remyelination by promoting clearance and degradation of myelin debris

Cell Rep. 2022 Nov 8;41(6):111591. doi: 10.1016/j.celrep.2022.111591.

Abstract

The progressive nature of demyelinating diseases lies in the inability of the central nervous system (CNS) to induce proper remyelination. Recently, we and others demonstrated that a dysregulated innate immune response partially underlies failure of CNS remyelination. Extensive accumulation of myelin-derived lipids and an inability to process these lipids was found to induce a disease-promoting phagocyte phenotype. Hence, restoring the ability of these phagocytes to metabolize and efflux myelin-derived lipids represents a promising strategy to promote remyelination. Here, we show that ApoA-I mimetic peptide 5A, a molecule well known to promote activity of the lipid efflux transporter ABCA1, markedly enhances remyelination. Mechanistically, we find that the repair-inducing properties of 5A are attributable to increased clearance and metabolism of remyelination-inhibiting myelin debris via the fatty acid translocase protein CD36, which is transcriptionally controlled by the ABCA1-JAK2-STAT3 signaling pathway. Altogether, our findings indicate that 5A promotes remyelination by stimulating clearance and degradation of myelin debris.

Keywords: ApoA-I mimetic peptide 5A; CP: Neuroscience; lipid droplet degradation; myelin debris clearance; phagocyte; remyelination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein A-I / metabolism
  • Demyelinating Diseases* / metabolism
  • Humans
  • Myelin Sheath / metabolism
  • Peptides / metabolism
  • Remyelination* / physiology

Substances

  • Apolipoprotein A-I
  • Peptides